Presentation is loading. Please wait.

Presentation is loading. Please wait.

FINANCING ARV EXPERIENCE FROM MALAYSIA BY SHA’ARI NGADIMAN, MD, MPH, EIP, AM MINISTRY OF HEALTH MALAYSIA.

Published byAnthony Gordon Modified over 9 years ago

Similar presentations

Presentation on theme: "FINANCING ARV EXPERIENCE FROM MALAYSIA BY SHA’ARI NGADIMAN, MD, MPH, EIP, AM MINISTRY OF HEALTH MALAYSIA."— Presentation transcript:

1 FINANCING ARV EXPERIENCE FROM MALAYSIA BY SHA’ARI NGADIMAN, MD, MPH, EIP, AM MINISTRY OF HEALTH MALAYSIA

2  Our Structure  National Strategic Plan on HIV and AIDS  Activities  Impacts of the activities  AIDS Expenditure  ARV & Logistic Cycle  Conclusion OUTLINE

3 OUR STRUCTURE Deputy Minister of Health State Health Office : 15 District Health Office : 141 Government Hospital : 138 Health Center : 985 Involve in process of financing, planning, procurement, distribution, monitoring etc Director Of Disease Control Dep. Director (Comm. Diseases) Sector HIV/STI Sector VBDCP Sector FWB&VPD Sector Zoonotic Sector TB/Leprosy Dep. Director (NCD) Dep. Director (Surveillance) Dep. Director (Env. /Occp H)

4 OUR STRUCTURE Director of Disease Control Dep. Director (Comm. Disease) Dep. Director (NCD) Dep. Director (Surveillance) Dep. Director (Env & Occp H) Head Sector HIV/STI SPAD Prevention SPAD Treatment and Care SPAD Harm Reduction SPAD Monitoring and Evaluation SPAD Counselor PAD Research Head Sector VBDCP Head Sector Zoonotic Head Sector TB/Leprosy Head Sector FWD&WPD SPAD State HIV/STI Officer

5 Target of NSP on AIDS 2011-15  80% MARPs reached prevention programmes  60% of MARPs use condoms consistently.  60% of IDUs use clean injecting equipment.  Able to eliminate vertical HIV transmission  80% ARV coverage for eligible PLHIV,

6 HIV NOTIFICATION IN MALAYSIA Cumulatifve HIV = 98,279 Cumulative deaths = 15,521 PLHIV (end of 2012) = 82,758 NEW HIV CASE PER 100,000 YEAR 20082009201020112012201320142015 TARGET16.015.314.613.913.212.511.711.0 ACHIEVED13.310.812.812.211.7

7 CUMMULATIVE ON HAART AS 31 DEC 2012 15,028 on ARV in 2012 39,000 Adult Eligible for ARV in 2012 (EPP Model)

8 Expenditure 2008 – 2012 ARV : 2011 – USD 16.10 mil 2012 – USD 20.41 mil USD 16.76 1 st Line ARV USD 3.65 2 nd Line ARV Expenditure (USD) DOMESTIC FUND FOR HIV WORKS 38%

9 ARV in Malaysia  Eligible criteria  Drugs listed in MOH Drug Formulary  By specialist  Available in hospitals and health centers with specialist  Also at hospitals or health centers without specialist through follow-up by visiting specialist  Can be dispense through Integrated Dispensing Medicine System

10 ARV in Malaysia  PLHIV above 15 yrs  1 st line – 91.7%  2 nd line – 8.0%  3 rd line – 0.3%  PLHIV below 15 yrs  1 st line – 71.0%  2 nd line – 27.0%  3 rd line – 2.0%

11 FLOW OF MOH DRUG FORMULARY REVIEW PANEL  Director-General of Health (DG) - Chairman  Deputy DG of Medical Services  Director of Pharmaceutical Services  8 Consultants in Public Services  3 Pharmacists in Public Services

12  List of drugs can be used by ALL MOH institutions  Serves as guide for the selection of drug therapy  First published in October 1983  Review 2 – 3 times a year  1530 drugs are listed  www.pharmacy.gov.my Objectives Provides the policy and administrative approach to : Control Promote Encourage rational, safe and cost effective drug prescribing and usage MOH DRUG FORMULARY

13 PROCUREMENT PRINCIPLES  Public accountability - Procurement should obviously reflect public accountability entrusted with the Government  Transparency - All procurement regulations, conditions, procedures and processes need to be clear and transparent to facilitate better understanding among suppliers and contractors.  Best value for money - Government procurement should yield the best returns for every Malaysian Ringgit spent in terms of quality, quantity, timeliness, price and source.  Open and fair competition - Processes involving Government procurement should offer fair and equitable opportunities to all those participating or competing in any procurement.  Fair dealing - All acceptable bids will be processed fairly based on current rules, policies and procedures.

14 Policies on Drug Procurement  Local product (priority)  Imported product : have to get approval from Ministry of International Trade and Industry & Ministry of Finance  Value for money  HOW?  Consession Company - Pharmaniaga Logistics Sdn Bhd (Approve Purchased Product List - APPL)  Central Contract (e-Tender/e-Bidding/Direct Negotiation)  Local Purchase by Quotation or Direct Purchase Drug Purchased in 2012

15 Importing Generic & Local Production  First Asian country issue Compulsory licensing in 2003  Local production of ARVs as part of our effort to confront the challenges of HIV/AIDS.  Currently, domestic pharmaceutical industry has capability to produce almost all dosage form and almost 80% of various categories in National Essential Drug List (NEDL) through the Malaysian Organization of Pharmaceutical Industries (MoPI).

16 Central Contract Generic Name Category Unit Procurement Data (2012) Line of Treatment QuantityValue (USD) 1Efavirenz 200 mg CapsuleA*pack of 90's2,388196,389.12First Line 2Efavirenz 600 mg TabletA/KKpack of 30's89,8375,559,544.78First Line 3Lamivudine 100 mg TabletA*pack of 28's30,4782,000,819.74First Line 4Lamivudine 150 mg TabletA/KKpack of 60's23,0771,152,003.84First Line 5 Stavudine 30 mg, Lamivudine 150 mg & Nevirapine 200 mg Tablet A/KKpack of 60's12,190660,288.42First Line 6 Tenofovir Disoproxil Fumarate 300 mg & Emricitabine 200 mg Tablet A*pack of 30's20,9361,071,923.20First Line 7 Tenofovir Disoproxil Fumarate 300 mg Tablet A*pack of 30's8,827310,710.40First Line 8 Zidovudine 300 mg & Lamivudine 150 mg Tablet A/KKTab/Cap4,532,4914,400,642.77First Line 9 Indinavir Sulfate 400 mg Capsule A*pack of 180's1,591214,848.64 Second Line 10 Lopinavir 200 mg and Ritonavir 50 mg Tablet A*pack of 120's6,1171,831,282.99 Second Line 11Ritonavir 100 mg CapsuleA*pack of 168's1,320225,984.00 Second Line Total 17,624,437.90

17 Local Purchase NoGeneric NameCategoryUnit Procurement Data (2012) Line of Treatment QuantityValue (USD) 1Stavudine 40mg (Tab/Cap)A*Tab/Cap702471.53First Line 2 Nevirapine 200mg (Tab/Cap)A/KKTab/Cap1,828,241439,737.40First Line 3Lamivudine 10mg/ml Oral Solution (Bottle)A*Bottle4,334321,993.28First Line 4Stavudine 30mg (Tab/Cap)A/KKTab/Cap897,181226,621.91First Line 5Stavudine 1mg/ml Oral Solution (Bot)A*Bottle33323.39First Line 6Zidovudine 100mg (Tab/Cap)A/KKTab/Cap206,831195,948.64First Line 7Zidovudine 10mg/ml Syrup (Bot)A*Bottle4,93388,070.40First Line 8Efavirenz 100mg (Tab/Cap)A*Tab/Cap00.00First Line 9Efavirenz 50mg (Tab/Cap)A*Tab/Cap54,33315,209.83First Line 10Zidovudine 1 % Inj. (Vial)AVial94744,480.21First Line 11Zidovudine 300mg (Tab/Cap)A*Tab/Cap328,63534,401.33First Line 12Didanosine 400mg (Tab/Cap)A*Tab/Cap24,21634,832.29Second Line 13Didanosine 100mg (Tab/Cap)A*Tab/Cap69,85133,137.58Second Line 14Didanosine 2g Oral Solution (Bot)A*Bottle39940,755.46Second Line 15Ritonavir 80mg/ml Oral Solution (Bot)A*Bottle225,674.24Second Line 16Didanosine 25mg (Tab/Cap)A*Tab/Cap54,041207,517.44Second Line 17Didanosine 250mg (Tab/Cap)A*Tab/Cap60,13767,790.28Second Line 18Raltegravir 400mg (Tab/Cap)A*Tab/Cap3,96053,539.20Second Line 19 Lopinavir/ Ritonavir Oral solution 533/13.3mg - Kaletra® (Bottle) ABottle2,455712,478.75Second Line Total 2,522,983.16

18 Drugs of Special Approval NoGeneric NameUnit Procurement Data (2012) Line of Treatment QuantityValue (USD) 1 Tenofovir DF 300 mg +Lamivudine 300mg Tab Tab18,35630,191.95First Line 2 Nevirapine 50mg/5ml Oral suspension (Bot) Bottle72914,683.24First Line 3 Lopinavir/ Ritonavir 100/25mg (Tab/Cap) Tab/Cap77,842143,620.74Second Line 4Abacavir 300mg (Tab/Cap)Tab/Cap54,41044,746.78Second Line 5Darunavir 300mg (Tab/Cap)Tab/Cap3,84016,896.00Second Line 6 Abacavir 600mg + Lamivudine 300mg Tab (listed in MOH Drug Formulary in Nov. 2012) Tab7,05012,994.56Second Line 7Abacavir 20 mg/ml (Bot)Bottle181,301.18Second Line 8Atazanavir 300mg (Tab/Cap)Tab/Cap450974.88Second Line Total 265,409.34 18

19 Logistic Cycle of ARV’s Supply Serving Clients Selection of ARV Forecasting & Procurement Inventory Management LOGISTIC INFORMATION MOH Drug Formulary Review Physician Ministry of Health (Pharmaceutical, Medical, Public Health) Individual hospital, health center Every level Central Contract Local Purchase Concession Company LIST A* : Consultant/ Specialist for specific indications only LIST A : Consultant/ Specialist LIST A/KK : Consultant/ Specialist/ Family Physician Specialist LIST B : Medical Officer LIST C : Paramedics LIST C+ : Midwifery Paramedics

20  System for ARV procurement worked!  Funded by Government (tax payers)  Changing pattern of the epidemic  Reaching 80% coverage for ARV  Continue and enhance current funding & activities  New inovation?  Review NSP 2011-15 CONCLUSION

21 21

Download ppt "FINANCING ARV EXPERIENCE FROM MALAYSIA BY SHA’ARI NGADIMAN, MD, MPH, EIP, AM MINISTRY OF HEALTH MALAYSIA."

Similar presentations

February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment 2006-2010 Department of HIV/AIDS.

February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
World Health Organization

World Health Organization
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.

ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool www.medicinespatentpool.org.

The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
HIV Treatment and Intellectual Property Rights: The Experience of the Medicines Patent Pool Esteban Burrone Melbourne – International AIDS Conference July.

HIV Treatment and Intellectual Property Rights: The Experience of the Medicines Patent Pool Esteban Burrone Melbourne – International AIDS Conference July.
MONITORING SYSTEM FOR THE ANTIRETROVIRAL THERAPY IN BRAZIL: LESSONS LEARNED AND FUTURE DIRECTIONS Marco Vitória, MD Brazilian STD/AIDS Programme - MOH.

MONITORING SYSTEM FOR THE ANTIRETROVIRAL THERAPY IN BRAZIL: LESSONS LEARNED AND FUTURE DIRECTIONS Marco Vitória, MD Brazilian STD/AIDS Programme - MOH.
Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department www.aids.gov.br July 20th, 2014 Evidence.

Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.
Stockouts: The legal framework Sasha Stevenson 25 July 2013.

Stockouts: The legal framework Sasha Stevenson 25 July 2013.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.

International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Pharmaceutical Services Unit Essential Medicines Management

Pharmaceutical Services Unit Essential Medicines Management
Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences

Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences
Application of an International Reference Price List to National Medicines Procurement Tenders Bada Pharasi, Gavin Steel, Jean-Pierre Sallet, SPS, Management.

Application of an International Reference Price List to National Medicines Procurement Tenders Bada Pharasi, Gavin Steel, Jean-Pierre Sallet, SPS, Management.
1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.

1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.
Procurement and Supply Management in Moldova Laurentiu IONESII.

Procurement and Supply Management in Moldova Laurentiu IONESII.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.

TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
National Medicine Policy

National Medicine Policy
RWANDA PERFORMANCE BASED SYSTEM: PUBLIC REFORMS Claude SEKABARAGA, MD, MPH Director policy, planning and capacity building Ministry of Health October 2008.

RWANDA PERFORMANCE BASED SYSTEM: PUBLIC REFORMS Claude SEKABARAGA, MD, MPH Director policy, planning and capacity building Ministry of Health October 2008.
Wilbert Bannenberg SARPAM

Wilbert Bannenberg SARPAM
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.

Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
© Prof. Rifat Atun. Imperial College London, 2007 The Dublin Declaration Beyond Promises Imperial College London 23 rd November 2007 Professor Rifat Atun.

© Prof. Rifat Atun. Imperial College London, 2007 The Dublin Declaration Beyond Promises Imperial College London 23 rd November 2007 Professor Rifat Atun.

Similar presentations

Ads by Google